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Background: Hospitalization periods at the exacerbation stage of COPD place a
major burden on the health services and entail substantial costs. Little is known,
however, about the corresponding burden on hospitals as the disease advances. We
therefore set out to determine from hospital discharge and cause of death registers
the overall burden on hospital resources occasioned by a COPD patient on a relative
time scale from ﬁrst admission to death, differentiated by age group, prognosis
and sex.
Methods: Data on all subsequent hospital treatment periods after the ﬁrst for
patients with COPD who were over 44 years of age on admission were gathered from
the Finnish National Research and Development Centre for Welfare and Health for
the period 1991–2001. The actual material for this study consisted of the data on
those patients who were alive after the ﬁrst treatment period but had died by 2001.
These were divided into three survival groups.
Results: The 8325 patients in this material had a total of 35,814 hospitalization
periods in 1991–2001, of which men accounted for 73.6%. A total of 1895 of the
patients (22.8%) had died within a year, 4257 (51.1%) within 1–5 years and 2173
(26.1%) after more than 5 years. Of those dying within a year, 20.9% had been in
hospital care, while of those who lived on for over a year, 4.5% were in hospital when
two-thirds of their remaining lifetime was still ahead of them and 7.3% when one-
tenth of that time was still ahead.
Conclusions: Almost one-fourth of the COPD patients had died within a year of ﬁrst
hospital admission for the disease. This group with a poor prognosis made abundantElsevier Ltd. All rights reserved.
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The COPD-induced hospitalization 295use of hospital services. The burden imposed on such services by severe COPD
patients is U-shaped, with hospital use increasing towards the end of their lives.
& 2006 Elsevier Ltd. All rights reserved.Introduction
COPD is a signiﬁcant community health problem. It
is a slowly progressing disease that is frequently
diagnosed at a relatively late stage, and its acute
exacerbation phases require hospital treatment,
often for protracted periods, so that this disease
entity alone accounts for two-thirds of all hospital
treatment costs for obstructive pulmonary dis-
eases.1 It is predicted that COPD will be the third
most common cause of death worldwide by 2020.2
A seriously affected patient with signiﬁcant con-
comitant diseases is likely to die within a year.3
Little is known, however, of the burden placed on
hospital services as the disease advances.
The uniquely comprehensive hospital registers
available in Finland provide rather good opportu-
nities to monitor the courses of diseases and
subsequent mortality, and also allow statistics to
be compared from 1 year to the next.
The purpose of this work was to determine the
numbers of days and periods of hospitalization
attributable to COPD and assess changes in the
mean length of treatment period on a relative time
scale from the ﬁrst admission to death. Patients
were distinguished by age, prognosis, sex, speci-
ality, the use of a secondary diagnosis and basic
cause of death.Material and methods
The National Research and Development Centre for
Welfare and Health (STAKES) is provided with data
on all patients treated in hospital in Finland,
including diagnoses, dates of admission and
discharge and social security numbers. All treat-n the patients.
ds in 1972–2001 with a ma
44 years of age in 1991–19
days at most among these
ients in 1991–2001
nding in death
ﬁrst treatment period but
ese patients in 1991–2001ment periods for which the main diagnosis was
COPD (diagnoses 491, 492 and 496, International
Classiﬁcation of Disease [ICD], 8th revision
1972–1986 and 9th revision 1987–1994 and J41,
J42, J43 and J44, 10th revision 1995–2001) were
extracted from the register for the period
1972–2001. A total of 327,513 such admissions
were found. An existing patient who had had no
recorded COPD-related hospital treatment period
in 1972–1990 and was ﬁrst discharged from hospital
on 1 January 1991 or later was recorded as a ‘‘new
admission’’ with COPD (i.e. was regarded as a ‘‘new
patient’’). Patients with incorrect or missing social
security numbers were excluded from the analyses
of new patients (1.6%) as were those patients aged
44 years or under at admission. The length of a
treatment period was obtained by subtracting the
date of admission from the date of discharge,
except that if these events occurred on the same
day the length was counted as 1 day. Periods of
more than 90 days (numbering 177 [0.8%] between
1991 and 2001) were excluded from the analysis.
The total number of new patients admitted from 1
January 1991–31 December 1996 was 12,597. Data
on deaths among these up to 31 December 2001
were obtained from the Statistics Finland.
A total of 8655 (68.7%) of the 12,597 new COPD
patients had died by the end of the year 2001, and
the 8325 of these who had been alive at the end of
the ﬁrst treatment period were taken to form the
actual material for the present study (Table 1).
Their use of hospital services was monitored on a
relative time scale from the ﬁrst admission to
death, for which purpose they were divided into
three groups according to the length of this
interval: less than a year, 1–5 years and more than
5 years. The material was analysed using SPSS for
Windows.in diagnosis of COPD 327,513
96 (with no treatment period 12,597
patients in 1991–2001 50,090
8655
327
dead by 31 December 2001 8325
35, 814
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The 12,597 new COPD patients registered in
1991–1996 had had a total of 50,090 treatment
periods for the disease by December 2001. The
mean age on admission in the case of the 35,814
treatment periods in the actual research data as a
whole that ended in death was 75.5 years and the
mean duration 8.4 days (SD 9.2), while the
corresponding ﬁgures for the patients who survived
were 73.5 years and 6.3 days (SD 6.3). A secondary
diagnosis was made use of in the case of 41.4% of
the treatment periods of the former kind and 35.0%
of the latter.Figure 2 Hospitalized women as percentages (on a
logarithmic scale) of all women (n ¼ 2198), on a relative
scale from the beginning of the ﬁrst treatment period to
death, grouped by length of survival (solid line: under 1
year, dashed line: 1–5 years, and dotted line: 5 years or
more).Patients
Of the 8325 patients alive after their ﬁrst hospita-
lization for COPD, 73.6% were men. The mean
survival time was 2.2 years (SD 2.1) for men and 2.4
years (SD 2.2) for women. The group who had died
within a year numbered 1895 patients (22.8% of the
total), with a mean age of 73.7 years (SD 8.2) on
admission, the group who had died within 1–5 years
contained 4257 patients (51.1%), mean age 72.6
years (SD 8.1), and the group who survived for more
than 5 years 2173 patients (26.1%) mean age 72.7
years (SD 8.2).
The proportions of men in the above groups who
were in hospital at the point when they had 2/3 of
the lifetime remaining to them still ahead of them
were 17.2%, 4.5% and 4.7%, respectively, with
corresponding proportions of 11.7%, 7.0% and 8.8%
when they had one tenth of their remainingFigure 1 Hospitalized men as percentages (on a loga-
rithmic scale) of all men (n ¼ 6127), on a relative scale
from the beginning of the ﬁrst treatment period to death,
grouped by length of survival (solid line: under 1 year,
dashed line: 1–5 years, and dotted line: 5 years or more).lifetime still ahead (Fig. 1). The corresponding
ﬁgures for the women were 20.4%, 4.5% and 4.3%
with two-third of their remaining lifetime ahead
and 10.3%, 6.5% and 7.0% with one-tenth (Fig. 2). It
should be noted, of course, that all the patients
were in hospital care when the period under
examination began. An average of 20.9% of those
who died within a year, 20.4% of the men and 21.9%
of the women, were in hospital after their ﬁrst
treatment period.Treatment periods
The 8325 patients who were alive after their ﬁrst
treatment period but had died by 31 December
2001 had had a total of 35,814 treatment periods in
the years 1991–2001. The men accounted for 74.7%
of these treatment periods, and men over 65 years
of age for 84.1% of the men’s total, while women
over 65 years of age accounted for 84.9% of all
treatment periods among the women. The patients
who died within a year accounted for 35.8% of the
total hospitalization periods and those who sur-
vived for more than 5 years for 12.6% (Table 2).Days of treatment
The 8325 patients had had a total of 300,447 days
of treatment over the years 1991–2001, of which
the men had accounted for 72.3% (Fig. 3). Men aged
65 years or over accounted for 86.4% of the men’s
total and women of that age for 87.8% of the
women’s total. Patients who died within a year
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Table 2 Numbers of treatment periods and
treatment days and mean lengths of hospital stay,
by sex and survival time.
Survival time in years
o1 y 1–5 y 45 y All
Treatment periods
Men 9780 13,780 3216 26,776
Women 3046 4701 1291 9038
Total 12,826 18,481 4507 35,814
Days of treatment
Men 91,476 103,645 21,957 217,078
Women 32,548 41,057 9764 86,369
Total 124,024 144,702 31,721 300,447
Length of hospital stay
Men 9.4 7.5 6.8 8.1
Women 10.7 8.7 7.6 9.2
Total 9.7 7.8 7.0 8.4
Figure 4 Durations of treatment periods (days) during
the years 1991–2001 for men and women hospitalized for
COPD who had died by 31 December 2001 (solid line: men
under 65 years, dashed line: men aged 65 years or over,
dotted line: women under 65 years, dashed and dotted
line: women aged 65 years or over), by relative survival
time (percentage of the time elapsing between the
beginning of the ﬁrst treatment period and death).
Figure 3 Total numbers of days of treatment for men
(black columns) and women (grey columns) hospitalized
for COPD who had died by 31 December 2001 during the
period 1991–2001, by relative survival time (percentage
of the time elapsing between the beginning of the ﬁrst
treatment period and death).
The COPD-induced hospitalization 297accounted for 41.3% of the treatment days and
those who survived for more than 5 years for 10.6%.Mean duration of treatment
The mean duration of the 35,814 treatment periods
reported was 8.4 days (SD 9.1), that for men being
8.1 days (SD 8.8), i.e. 7.0 days (SD 7.7) for those
under 65 years of age and 8.3 days (SD 8.9) days for
those over 65 years, while the mean duration for
women was 9.2 days (SD 9.9), 7.5 days (SD 8.2) forthose under 65 years and 9.5 days (SD 10.2) for those
over 65 years (Fig. 4).Speciality, secondary diagnoses and basic
cause of death
45.6% of the treatment periods for patients who
had died within a year, 52.9% for those who had
died within 1–5 years and 59.3% for those who had
died after more than 5 years took place in a
department of respiratory diseases, whereas a
secondary diagnosis was referred to in 42.3%,
39.2% and 41.6% of the cases in these groups,
respectively. COPD was quoted as the basic cause of
death in the Statistics Finland reports in 54.1%,
49.9% and 40.8% of the cases in these groups,
respectively.Discussion
Conditions for health surveys among the general
population based on register data are better in
Finland than in most other countries, as the
registers have good coverage and the quality of
the data is quite high quality for research
purposes.4,5 In addition, the ubiquitous use of
social security numbers enables data from different
registers to be combined. The Finnish hospital
discharge register has been shown to be highly
reliable, showing a conformity with hospital re-
cords that is as high as 95%.6 Only two disease
classiﬁcations were in use over the period
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scarcely be said to have varied very much. Morover,
the diagnoses of COPD made within the Finnish
health care system can certainly be regarded
as reliable, as they were mostly made by specialists
in pulmonary diseases during the whole investiga-
tion period, for the purpose of entitling patients
to the reimbursement of medication costs. The
results may, however, have been inﬂuenced
by changes in treatment praxis and patient’s
co-morbidities, especially treatments with other
main diagnoses.
Chronic obstructive bronchitis (J44), emfysem
(J43) and chronic bronchitis (J41, J42) form
together a combination of symptoms of chronic
obstructive pulmonary disease. For this the separa-
tion of the diagnoses to a clear COPD can be
difﬁcult in our material. The most frequently used
code for COPD in the 10th version of the Interna-
tional Classiﬁcation of Diseases, ‘‘J44’’, accounts
for 85.9% of the treatment periods for COPD
recorded here for the time this version was used.
COPD is frequently underdiagnosed,7 but this is
especially true in mild cases, where the risk of
hospitalization for the disease is less marked than
in the obviously more severe cases considered here.
So our results have not been greatly affected by
this problem.
Only COPD patients over 44 years of age were
considered here, because diagnoses of this disease
that require hospitalization are rare at younger
ages and usually involve a concurrent diagnosis of
asthma. The purpose of limiting the permitted
length of treatment period was to exclude patents
in long-term institutional care.
The fact that the use of health services was most
pronounced among the more elderly COPD patients
is in agreement with observations in America that
hospitalization periods for such patients are long
and are frequent at the acute exacerbation stage.8
Such features reﬂect the degree of severity of the
disease and are connected with increased hospital
use and a higher risk of death within a short space
of time.9,10 In other words, they imply the onset of
the terminal stage in the disease.
The observation that men accounted for about
three-fourths of the patients treated in hospital
and the same proportion of the total treatment
periods may be attributed to smoking habits, with a
delay of a few decades. More recent ﬁgures, for
1998, nevertheless show that 30% of men in Finland
and 20% of women are smokers, i.e. the proportion
of women smoking has doubled over the last 50
years while the proportion of men has decreased by
a factor of three (http://www.ktl.ﬁ/org/esittely/
huttunen/tupakointi-suomessa.pdf, in Finnish).Connors et al.10 reported a higher proportion of
patients dying within a year of hospitalization for
the acute exacerbation phase, 43%, but his cases
had more serious COPD on average than ours, as
they all involved hypercapnia. Almagro et al.11 and
Groenewegen et al.,12 with smaller series, arrived
at similar ﬁgures to ours, mortalities of around 23%
in the ﬁrst year. Our observations were that about a
half of the patients died within 5 years of their ﬁrst
treatment period. It should be mentioned that the
life expectation for Finnish people aged 72 years at
the time in question was 11.1 years for men and
13.9 years for women.21 An average of about 20% of
those who died within 1 year were in hospital care
from their ﬁrst hospitalization onwards, whereas
this ﬁgure was only 7% among those with a better
prognosis. In accordance with the customary
distribution of treatment responsibilities, more of
the patients with a poor prognosis were treated
within the basic health care service than was the
case with the other groups, whereas the use of a
secondary diagnosis was not related to the prog-
nosis. It has been shown earlier that COPD patients
who die within a year of their previous hospitaliza-
tion period spend a ﬁfth of the last 6 months of
their lives in hospital.3
The men and women in our material who died
within a year accounted for about 40% of all the
days of treatment recorded, and those who
survived for more than 5 years for only just over
10%. Treatment days tended to accumulate most in
the earlier and late stages of the disease. Patients’
use of hospital services tended to decrease for
some time after the ﬁrst admission for COPD,
increasing again in the time leading up to death.
Thus, hospital use could be described in terms of a
U-shaped curve, a fact partly attributable to the
hospitalization days accumulating during the ﬁrst
treatment period. Hospital use among those surviv-
ing for more than a year was least pronounced
when two-third of the lifetimes remaining to them
still lay ahead.
Soler et al.13 have noted that 60% of the use of
hospital services by COPD patients is attributable to
a small group (12.2%) who have a more serious form
of the disease, while Andersson et al.14 reports that
the costs of treatment are distributed in proportion
to severity and tend to be concentrated at the
terminal stage. Mukamel et al.,15 who examined
the last 3 years before death, found that resource
use started to increase about 7 months before
death, with a substantial increase, dominated by
hospital use, about 1 month prior to death.
The fact that the mean duration of hospitaliza-
tion was a couple of days longer for those dying
within a year than for those surviving longer is
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the former cases. On the other hand, the mean
duration of treatment was greatest in the terminal
stage, as death was approaching, which presumably
reﬂects an advanced stage in the disease, where-
upon costs can be expected to increase.
Since it was those who died within a year of their
ﬁrst treatment period that placed the greatest
burden on the hospitals, it would be important to
identify these cases, develop out-patient treat-
ment routines for them and increase home care.
The advantages of home care at the exacerbation
stage of COPD have been clearly demonstrated, in
that such patients had less emergency visits,
possessed more information about their disease
and enjoyed an improved quality of life. Costs were
also only two-thirds of those of hospital treat-
ment.16
Severe COPD requiring hospital treatment is a
progressive disease that kills within a relatively
short space of time, and our ﬁndings suggest that
the burden on hospital use tends to increase as the
disease approaches the terminal stage. Little
palliative treatment is usually available at this
stage.17 COPD patients and their next-of-kin need
more information from the attending physician on
the progress of the disease, the prognosis and the
alternatives available for terminal-stage treat-
ment,18,19 as it is at this point that decisions have
to be taken in the light of the prognosis regarding
whether or not to resort to invasive ventilation and
intensive care.20References
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